论文部分内容阅读
目的:评价孟鲁司特与布地奈德和复方异丙托溴胺雾化吸入联用对小儿呼吸道感染后咳嗽的临床疗效。方法:选取2011年10月—2014年10月小儿呼吸道感染后咳嗽患儿60例,将其分为观察组与对照组,各30例;观察组患儿给予孟鲁司特与布地奈德和复方异丙托溴胺雾化吸入联用治疗,对照组患儿给予口服孟鲁司特治疗,比较两组患儿治疗后临床症状和咳嗽消失时间的变化情况。结果:观察组患儿治疗后临床总有效率为80.00%显著高于对照组为50.00%(P<0.05);观察组患儿治疗后呼吸困难、哮鸣音、咳嗽咳痰、气喘症状体征消失时间明显优于对照组(P<0.05);两组患儿用药后不良反应的发生率经比较其差异无统计学意义(P>0.05)。结论:孟鲁司特与布地奈德和复方异丙托溴胺雾化吸入联用治疗小儿呼吸道感染后咳嗽的临床疗效优于单用孟鲁司特治疗。
OBJECTIVE: To evaluate the clinical efficacy of montelukast, budesonide and ibuprofen in combination with atomization inhalation on cough after pediatric respiratory infection. Methods: Sixty children with cough after pediatric respiratory infection were selected from October 2011 to October 2014. The patients were divided into observation group and control group, with 30 cases in each group. The patients in observation group were given montelukast and budesonide, Compound ipratropium bromide aerosol inhalation therapy, control group of children given oral montelukast treatment, the clinical symptoms and cough disappear time changes between the two groups were compared. Results: After treatment, the total effective rate of observation group was 80.00%, which was significantly higher than that of the control group (50.00%, P <0.05). After treatment, dyspnea, wheeze, cough and phlegm were disappeared in the observation group The time was significantly better than the control group (P <0.05); two groups of children after treatment the incidence of adverse reactions by the difference was not statistically significant (P> 0.05). Conclusion: The clinical efficacy of montelukast with budesonide and compound ipratropium bromide inhalation in treating children with respiratory tract infection after cough is better than montelukast alone.